Delmar Pharma (DMPI) 0.7100 $DMPI SeeThruEquity Issues

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Delmar Pharma (DMPI) 0.7100 $DMPI

SeeThruEquity Issues Update on DelMar Pharmaceuticals Highlighting Data Presented at American Association for Cancer Research
ACCESSWIRE - Tue May 12, 8:02AM CDT
NEW YORK, NY / ACCESSWIRE / May 12, 2015 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a 2Q15 update note on DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.

DelMar Pharmaceuticals to Present Additional Data on VAL-083 as a Potential Treatment for Temozolomide-Resistant GBM at AACR Advances in Brain Cancer Research Conference
PR Newswire - Thu May 07, 7:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it will be presenting additional data on VAL-083 (dianhydrogalactitol) as a potential new treatment for temozolomide-resistant glioblastoma multiforme (GBM) at the American Association for Cancer Research (AACR) Advances in Brain Cancer Research conference being held May 27-30, 2015, in Washington, DC.

DelMar Pharmaceuticals to Present Data Supporting the Development of VAL-083 in Refractory Glioblastoma Multiforme and Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
PR Newswire - Thu Apr 30, 6:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", today announced that it will be presenting new data related to the development of lead product candidate VAL-083 (dianhydrogalactitol) at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 29-June 2, 2015, in Chicago, Illinois.

DelMar Pharmaceuticals Presents Promising Preclinical Data on VAL-083's Potential to Treat Temozolomide-Resistant Glioblastoma Multiforme (GBM)
PR Newswire - Mon Apr 20, 12:00PM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced promising preclinical data at the 106th Annual Meeting of the American Association for Cancer Research (AACR) Annual Meeting on the potential for its lead product candidate VAL-083 (dianhydrogalactitol) to treat patients with temozolomide-resistant glioblastoma multiforme (GBM).

DelMar Pharmaceuticals Presents Updated Clinical Data on Phase I/II Study of VAL-083 in Refractory Glioblastoma Multiforme (GBM)
PR Newswire - Mon Apr 20, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced updated clinical data on the identification of maximum tolerated dose (MTD) from its Phase I/II study of its lead product candidate VAL-083 (dianhydrogalactitol) in patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer.

DelMar Pharmaceuticals Presents Positive Preclinical Data on VAL-083 for Treatment of Non-Small Cell Lung Cancer at the American Association of Cancer Research Annual Meeting
PR Newswire - Sun Apr 19, 12:00PM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced positive preclinical data on its lead product candidate VAL-083 (dianhydrogalactitol) for treatment of platinum drug-resistant non-small cell lung cancer (NSCLC) and as a potential combination therapy option in newly diagnosed NSCLC patients.

DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma
PR Newswire - Thu Apr 16, 7:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that the Mayo Clinic Cancer Center has been added as a clinical trial site for the ongoing, multicenter Phase I/II study of VAL-083 in patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer.

DelMar Pharmaceuticals Announces Panel Participation in Cancer Advance Boston Conference on April 14, 2015
PR Newswire - Tue Apr 07, 7:00AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that Jeffrey Bacha, President and CEO, will be a panelist at Cancer Advance Boston, a networking conference of the Boston Biotech Conference series, being held April 13-14, 2015, at the Joseph B. Martin Conference Center at Harvard Medical School in Boston, Massachusetts.

DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors
PR Newswire - Wed Apr 01, 7:05AM CDT
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", today announced that it has appointed biopharmaceutical industry veteran, Erich Mohr, Ph.D., R.Psych., to its Board of Directors as an independent director.

SeeThruEquity Issues Update on DelMar Pharmaceuticals
ACCESSWIRE - Mon Mar 09, 8:45AM CDT
NEW YORK, NY / ACCESSWIRE / March 9, 2015 / SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a 2Q15 update note on DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a biotechnology company focused on proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments.

DelMar Pharmaceuticals to Present at the 27th Annual ROTH Conference on March 10, 2015
PR Newswire - Tue Mar 03, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it will be presenting at the 27th Annual ROTH Conference being held March 8-11, 2015, at The Ritz-Carlton, Laguna Niguel, in Dana Point, California.

DelMar Pharmaceuticals Receives Notice of Allowance of Fourth U.S. Patent Covering Methods of Use and Compositions for VAL-083
PR Newswire - Mon Mar 02, 10:17AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) (DelMar and the Company), a company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application number 13/817,096 entitled, "Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted hexitols such as dianhydrogalactitol and diacetyldianhydrogalactitol."

DelMar Pharmaceuticals Announces December 31, 2014 Financial Results and Provides Corporate Update
PR Newswire - Thu Feb 12, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company" today announced the filing of its financial statements for the six months ended December 31, 2014 and provided an overview of recent Company highlights and expected near-term milestones. Management will host an investor update conference call and live webcast to discuss recent highlights and the Company's plans for the continued advancement of its business plan on Tuesday, February 17, 2015, at 1:30 p.m. PST / 4:30 p.m. EST.

DelMar Pharmaceuticals names Lynda Cranston to board
M2 - Thu Feb 12, 6:41AM CST
Cancer therapies company DelMar Pharmaceuticals (OtherOTCMPI) said on Wednesday that Lynda Cranston, BScN, MScN, ICD.D, has been elected as an independent director to its board of directors.

DelMar Pharmaceuticals Appoints Lynda Cranston, BScN, MScN, ICD.D, to the Board of Directors
PR Newswire - Wed Feb 11, 7:13AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", today announced that it has appointed Lynda Cranston, BScN, MScN, ICD.D, to its Board of Directors as an independent director. Ms. Cranston serves as Chair of the Company's newly formed Governance and Compensation Committee.

DelMar Pharmaceuticals Completes Offer to Exchange Common Stock for Outstanding Warrants
PR Newswire - Tue Feb 10, 8:35AM CST
DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the "Company", today announced that it has completed a tender offer to exchange ("Offer to Exchange" new shares of the Company's common stock ("Shares" for outstanding Company warrants to purchase up to 5,964,738 shares of common stock (the "Warrants" (at a ratio of one Share for every three Warrants tendered). Upon expiry of the Offer to Exchange, 1,591,875 Warrants were exchanged, and the Company will issue 530,625 new shares of common stock.

DelMar Pharmaceuticals awarded notice of allowance for third US patent for VAL-083, expanding to three US patents and one international patent
M2 - Wed Jan 14, 6:54AM CST
Cancer therapies company DelMar Pharmaceuticals (Other OTCMPI) reported on Tuesday the receipt of the US Patent and Trademark Office's (USPTO) notice of allowance for patent application number 14/083,135, entitled, "Analytical Method for Analyzing and Determining Impurities in Dianhydrogalactitol (VAL-083)".

DelMar Pharmaceuticals Receives Notice of Allowance for Third US Patent for VAL-083
PR Newswire - Tue Jan 13, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar", "the Company" today announced that the U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance for patent application number 14/083,135, entitled, "Analytical Method for Analyzing and Determining Impurities in Dianhydrogalactitol (VAL-083)".

DelMar Pharmaceuticals Provides Update on VAL-083 Clinical Trial and Outlines Corporate Objectives for 2015
PR Newswire - Mon Jan 12, 7:00AM CST
DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar", "the Company) provided an update on the Company's ongoing Phase I/II clinical trial with VAL-083 as a potential new treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. In addition, DelMar outlined its corporate objectives for 2015.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PSEG Long Island Warns Customers on QR Payment Scams

Updated Category News Views 0

Holiday panic is a thief's favorite crowbar, and Long Island households are plainly in the crosshairs. PSEG Long Island used Utility Scam Awareness Day on Nov. 18 to warn customers about impersonators demanding immediate payment under threat of a power shutoff. The central message, “Think Before You Scan,” is not flashy corporate wallpaper. It is practical advice for...

Continue Reading
LEPAS AURA Signals a Sharper Design Bet for Future Cars

Updated Category News Views 96

A porcelain-smooth concept car is not a balance sheet, but it can tell you where a young automotive brand intends to spend its attention. LEPAS unveiled AURA in October at its first Global Elegant Lifestyle Week, presenting it as the brand's first global concept car and a fresh expression of its Leopard Aesthetics design language. That matters because AURA is plainly not...

Continue Reading
Washington-to-Asia Advisory Deal Targets Policy Risk

Updated Category News Views 37

Policy bottlenecks are becoming a cost center across Southeast Asia. That is the plain-English backdrop for the strategic partnership announced November 18, 2026, by Beacon Global Strategies and Vriens & Partners. Neither firm is selling a factory, a chip design, or a new energy project. They are selling something companies increasingly cannot afford to improvise: a...

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 304

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
1095 Days Finds the Army's Long, Ordinary War Life

Updated Category News Views 89

A cracked barracks window can explain more than a polished battlefield legend. Dean R. Cherry's 1095 Days: Three Years in the Green Machine, newly released by Palmetto Publishing, puts its weight on the parts of Army life that war stories often shove into the background: cold, waiting, paperwork, arbitrary rules, lousy living conditions, and the private mental math of...

Continue Reading
Fapon’s Enzyme Push Meets Diagnostics Reality at AMP

Updated Category News Views 85

Enzymes rarely get applause at industry meetings, but they can quietly decide whether a diagnostic workflow behaves or becomes a lab headache. Fapon used its AMP 2026 appearance in Seattle to make that unglamorous case: better enzyme design may help assays move faster and keep working when samples get messy. The company wrapped up the November 10–14 meeting after...

Continue Reading
Physiatry or Orthopedics: Sorting Out Pain Care Choices

Updated Category News Views 22

Pain care gets muddled the minute people assume every ache needs the same doorway. Dr. Mala Young, a physical medicine and rehabilitation expert in Ann Arbor, Michigan, makes a useful distinction: a physiatrist and an orthopedic doctor may both see pain, mobility trouble, and injury, but they are not interchangeable. That sounds obvious until someone is staring at back...

Continue Reading
Rochester Truck Crashes Demand a Different Liability Map

Updated Category News Views 13

An 80,000-pound rig does not leave anybody the luxury of treating a wreck like a bent-fender dispute. That is the uncomfortable point behind Rochester attorney John Wright's discussion of truck crashes around I-390 and I-490. The physical damage may be obvious, but the legal story can be buried in dispatch systems, maintenance files, driver logs and corporate decisions...

Continue Reading
Lummus-Versalis Deal Adds Nine Elastomer Technologies

Updated Category News Views 56

Nine elastomer technologies do not make a flashy headline, yet this is the sort of chemical-industry move that can matter long after the applause dies down. Lummus Technology and Versalis have expanded their partnership to cover nine elastomer technologies. That is the disclosed fact, and it is meaningful on its own. The release does not lay out contract value, duration,...

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 271

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading

Top 5 Most Recently Viewed Articles

SK Chemicals Delivers Sustainable Innovation at ECS 2025

Updated Category News Views 484

SK Chemicals at the European Coatings Show 2025 SK chemicals has proudly participated in the European Coatings Show (ECS) 2025, marking a significant moment for the company as it engages in marketing its innovative materials. This event is known for attracting key players in the coatings and paint sector, and this year was no exception, with over 1,000 exhibitors and more...

Continue Reading
Analyzing TJX Companies' Increased Short Interest Trends

Updated Category News Views 230

Understanding the Rise in TJX Companies' Short Interest The short interest for TJX Companies (NYSE: TJX) has seen a significant uptick, now standing at 14.55 million shares sold short, which constitutes 1.29% of its float. This marks a 21.7% increase since the prior reporting period. Given the current trading volume, traders would require approximately 2.49 days to cover...

Continue Reading
IGT Expands Collaboration with La Française des Jeux for Instant Tickets

Updated Category News Views 69

IGT Expands Collaboration with La Française des Jeux Company to deliver top-performing instant ticket games to one of the world's largest lotteries International Game Technology PLC (NYSE: IGT) has officially entered a three-year partnership with La Française des Jeux (FDJ), the esteemed operator of the French National Lottery. This significant agreement follows a...

Continue Reading
Archer Expands Footprint with New Manufacturing Facility Opening

Updated Category News Views 267

Archer Expands Footprint with New Manufacturing Facility Opening New state-of-the-art facility doubles manufacturing capacity and adds more than 200 local jobs Archer, one of the fastest-growing meat snack brands in the U.S., is celebrating a significant milestone with the grand opening of its new manufacturing facility. This latest addition in Vernon, California,...

Continue Reading
Bumble Faces Downgrade from KeyBanc Amid Revenue Concerns

Updated Category News Views 309

Bumble Inc (NASDAQ: BMBL) took a hit when KeyBanc downgraded its rating from 'Overweight' to 'Sector Weight', shaking the confidence of many investors. The downgrade was more than just a simple reassessment; it became a catalyst for a stock value decline in premarket trading that had traders watching their screens with bated breath. KeyBanc Downgrade: A Harbinger of...

Continue Reading